A patient with a squamous‑cell carcinoma lesion who had cellulitis treated two months ago now shows recurrent infection; can I prescribe another course of cephalexin (Keflex)?

Recurrent Cellulitis in a Patient with Squamous Cell Carcinoma

Yes, you can prescribe another course of cephalexin for this recurrent cellulitis, but you must first rule out malignant progression of the SCC lesion itself and aggressively address modifiable risk factors before considering long-term prophylaxis. 1, 2

Immediate Diagnostic Considerations

Critical first step: Obtain a biopsy of the lesion if it appears atypical or fails to respond to a full antibiotic course, because SCC can present as cellulitis and may be mistaken for simple infection. 2

• One case report documents a patient whose facial "cellulitis" did not respond to full-course antibiotics and turned out to be newly diagnosed SCC after biopsy. 2
• Malignancy should be suspected in all unusual presentations, particularly when infection recurs at the exact site of a known SCC lesion. 2
• If the clinical appearance suggests progression of the underlying SCC (ulceration, induration, failure to respond), biopsy before treating as simple cellulitis. 2

Acute Treatment of the Current Episode

For typical non-purulent cellulitis, cephalexin (or another β-lactam) remains first-line therapy. 1, 3

• Dosing: Cephalexin 500 mg four times daily for 5 days is sufficient when clinical improvement is evident by day 5. 4, 1
• A pilot trial suggests high-dose cephalexin (1000 mg four times daily) may reduce treatment failure (3.2% vs. 12.9% with standard dose), though minor adverse effects increase. 5
• β-lactam monotherapy achieves cure rates of approximately 96% in typical cellulitis; MRSA coverage is unnecessary unless specific risk factors exist (penetrating trauma, purulent drainage, injection drug use, or concurrent MRSA infection elsewhere). 1, 3
• Do not add routine MRSA coverage for non-purulent cellulitis—this is a strong IDSA recommendation. 1

FDA-Approved Indications for Cephalexin

• Cephalexin is FDA-approved for skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes. 6
• Culture and susceptibility testing should be initiated prior to and during therapy when feasible. 6
• Prolonged use may result in overgrowth of nonsusceptible organisms; careful observation is essential. 6

Risk-Factor Assessment for Recurrence

Before considering prophylaxis, identify and aggressively treat modifiable risk factors—this is a strong IDSA recommendation. 1

• Lymphedema or chronic edema is the single most important modifiable risk factor for recurrent cellulitis. 1
• Interdigital tinea pedis (toe-web fungal infection) is a major preventable contributor; examine toe-webs carefully and treat aggressively with antifungals. 1
• Venous insufficiency warrants compression therapy and formal vascular evaluation. 1
• Obesity independently increases recurrence risk; weight-reduction counseling is recommended. 1
• Stasis dermatitis (venous eczema) requires ongoing skin-care measures and emollients. 1
• Prior trauma or surgery to the affected area creates persistent vulnerability. 1

SCC-Specific Considerations

• The presence of an underlying SCC lesion may create local tissue disruption, impaired lymphatic drainage, and compromised skin barrier function—all of which predispose to recurrent infection. 1
• If the SCC is locally advanced or has caused tissue destruction, surgical debridement or definitive oncologic treatment may be necessary to prevent further infectious complications. 7

When to Consider Antibiotic Prophylaxis

Initiate prophylaxis only after ≥3–4 episodes per year AND after addressing modifiable risk factors. 1

• First-line prophylaxis: Penicillin V 250 mg twice daily for 4–52 weeks. 1
• Alternative (penicillin allergy): Erythromycin twice daily for 4–52 weeks. 1
• Parenteral option: Benzathine penicillin G 1.2–2.4 million IU intramuscularly every 2–4 weeks. 1
• Prophylaxis should be continued indefinitely as long as predisposing risk factors persist. 1
• Do not start prophylaxis without first correcting modifiable risk factors—this is a strong IDSA recommendation. 1

Decolonization Strategies (Weak Evidence)

• For recurrent Staphylococcus aureus cellulitis, the IDSA suggests a 5-day decolonization regimen: twice-daily intranasal mupirocin, daily chlorhexidine washes, and regular laundering of towels, sheets, and clothing (weak recommendation, low-quality evidence). 4, 1
• Randomized trials show that mupirocin alone or chlorhexidine cloths alone do not significantly reduce cellulitis recurrence rates. 1

Common Pitfalls and Caveats

• Do not overlook toe-web examination: Untreated tinea pedis is a major preventable risk factor. 1
• Do not assume simple cellulitis in the setting of a known SCC: Biopsy if the lesion appears atypical or fails to respond to antibiotics. 2
• Do not prescribe cephalexin in the absence of a proven or strongly suspected bacterial infection: This increases the risk of drug-resistant bacteria. 6
• Caution with concurrent acid-suppressive therapy: One study found a 40% failure rate for cephalexin versus 20% for comparator antibiotics, possibly related to concurrent acid suppression. 8
• Elevate the affected limb during acute cellulitis to facilitate gravity-driven edema drainage. 1

Follow-Up and Monitoring

• Annual recurrence rates after a prior episode range from 8% to 20% when no prophylaxis is used. 1
• The risk of recurrence escalates with each subsequent episode, creating a self-perpetuating cycle if underlying factors remain unaddressed. 1
• Recurrences tend to occur at the same anatomic site as prior infections because the underlying tissue abnormalities persist. 1